Sunday 18 October 2026
Export SPRB’s income statement to Excel — free account
Spruce Biosciences, Inc.
SPRB Healthcare Biotechnology
Spruce Biosciences, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $4.9 million, down 51.3% from fiscal 2023. In the quarter to June 2026, revenue fell 75.9%, EPS fell 90.9%, free cash flow fell 152.1% and total debt rose 427.2%, each against the same quarter a year earlier.
39.65
1.82
−4.39%
Follow SPRB
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | — | — | 0.00 | 0.00 | — |
P/S ratio |
— | — | — | — | — | — | 845.29 | 264.58 | — |
Altman Z-Score |
— | — | — | — | — | — | 181.29 | 36.60 | — |
P/FCF ratio |
— | — | — | — | — | — | 0.00 | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | — | — | (1.71) | (20.34) | — |
P/Operating CF |
— | — | — | — | — | — | (760.83) | (62.84) | — |
P/B ratio |
— | — | — | — | — | — | 111.47 | 45.08 | — |
Price to Tangible BV |
— | — | — | — | — | — | 111.47 | 45.08 | — |
EV/Sales |
— | — | — | — | — | — | 836.07 | 257.05 | — |
EV/EBITDA |
— | — | — | — | — | — | 0.00 | 0.00 | — |
EV/Operating CF |
— | — | — | — | — | — | (253.50) | (22.56) | — |
EV/FCF |
— | — | — | — | — | — | (253.43) | (22.55) | — |
Quick Ratio |
— | 1.52 | 0.91 | 16.10 | 10.03 | 6.35 | 3.94 | 2.54 | 4.85 |
Current Ratio |
— | 1.76 | 1.08 | 16.43 | 10.36 | 6.72 | 4.18 | 2.90 | 5.17 |
Net Debt/EBITDA |
— | 0.41 | (0.04) | 5.20 | 2.00 | 1.57 | 1.77 | 0.66 | 1.34 |
Debt/Assets |
0.00% | 0.00% | 94.74% | 2.75% | 4.14% | 5.74% | 3.21% | 3.86% | 0.00% |
Debt/Equity |
— | 0.00 | (1.57) | 0.03 | 0.05 | 0.07 | 0.04 | 0.06 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.11 | 0.07 | 0.00 |
Operating CF/Net income |
— | 0.87 | 0.96 | 0.93 | 0.85 | 0.90 | 0.69 | 1.06 | 0.86 |
Capex/Depreciation |
— | 0.00 | (0.33) | (2.06) | (0.49) | (0.09) | 0.01 | 0.00 | 0.00 |
Interest Coverage |
— | — | (201.65) | (91.07) | (121.93) | (112.58) | (107.65) | (182.90) | (405.70) |
| — | 40.70% | 54.04% | (49.73%) | (32.43%) | (51.35%) | (66.10%) | (100.70%) | (109.24%) | |
| — | (412.90%) | (276.50%) | (35.25%) | (29.23%) | (43.54%) | (50.55%) | (71.12%) | (79.34%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | (95.12%) | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | (476.69%) | (3,750.14%) | (19.61%) | (50.94%) | (64.90%) | (61.66%) | (183.14%) | (92.72%) |
Average Days of Receivables |
— | — | — | — | — | — | 0.00 | 0.00 | — |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 489.96% | 945.18% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 125.38% | 298.19% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | 0.00% | 0.00% | 45.81% | 108.90% | 0.00% |
Graham Net Nets |
— | — | — | — | — | — | 0.01 | 0.02 | — |
Graham Number |
— | — | — | — | — | — | 0.00 | 0.00 | — |
Earnings Yield |
— | — | — | — | — | — | (0.56%) | (4.07%) | — |
Free Cash Flow Yield |
— | — | — | — | — | — | (0.39%) | (4.31%) | — |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 19.70 | 8.93 | 0.00 |
Operating CF per Share |
— | (0.38) | (1,236.96) | (345.28) | (115.47) | (133.22) | (64.96) | (101.75) | (43.45) |
Capex per Share |
— | 0.00 | (0.39) | (0.93) | (0.30) | (0.03) | (0.01) | 0.00 | 0.00 |
Free Cash Flow per Share |
— | (0.38) | (1,237.35) | (346.21) | (115.77) | (133.24) | (64.98) | (101.75) | (43.45) |
Cash per Share |
— | 0.18 | 384.71 | 1,971.77 | 286.35 | 252.72 | 188.09 | 70.46 | 63.76 |
Shareholders Equity per Share |
— | 0.09 | (276.86) | 1,874.87 | 358.45 | 218.88 | 149.37 | 52.40 | 55.43 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.09 | (276.86) | 1,874.87 | 358.45 | 218.88 | 149.37 | 52.40 | 55.43 |
Free Cash Flow |
— | (8.57) | (12.62) | (27.59) | (35.97) | (41.69) | (33.28) | (55.96) | (33.33) |
Working Capital |
— | 2.07 | 0.35 | 150.63 | 83.02 | 71.16 | 77.72 | 28.96 | 42.03 |
Capital Expenditures |
— | — | 0.00 | (0.07) | (0.09) | (0.01) | (0.01) | — | — |
Net Current Asset Value |
— | 2.07 | (2.86) | 146.94 | 76.78 | 66.45 | 74.75 | 27.82 | 41.61 |
EV/EBIT |
— | — | — | — | — | — | 0.00 | 0.00 | — |
Capex to Sales |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Price to Operating Income |
— | — | — | — | — | — | 0.00 | 0.00 | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cash ROIC |
— | (138.63%) | (227.61%) | (8.87%) | (17.50%) | (27.34%) | (18.89%) | (80.73%) | (36.45%) |
Accounts Receivable Turnover |
— | — | — | — | — | — | 0.00 | 0.00 | — |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 839,500.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Payables |
— | 2.09 | 2.09 | 2.75 | 3.23 | 2.12 | 2.38 | 2.31 | 1.12 |
Average Assets |
— | 2.39 | 4.73 | 83.79 | 144.68 | 106.07 | 94.80 | 74.58 | 49.12 |
Average Common Equity |
— | (24.22) | (24.22) | 59.40 | 130.40 | 89.93 | 72.50 | 52.67 | 35.67 |
Columns are period end dates